ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO640

Serum Magnesium, Mortality, and Cardiovascular Disease in CKD and ESRD Patients: A Systematic Review and Meta-Analysis

Session Information

Category: Fluid and Electrolytes

  • 902 Fluid and Electrolytes: Clinical

Authors

  • Xiong, Jiachuan, Xinqiao hospital, Chongqing, China
  • He, Ting, Department of Nephrology, Xinqiao Hospital, Chongqing, China
Background

Magnesium plays an independent pathogenic role in chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients. However, the results of these studies were somewhat underpowered and inconclusive.

Methods

Literature was identified by searching PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials (CENTRAL). Unadjusted and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs) were pooled.

Results

The results showed that there was a strong association between hypomagnesemia and the risk of all-cause mortality in patients with CKD and ESRD (HR 1.32; 95% CI1.19–1.47; p < 0.00001) after multivariable adjusted. On the contrary, hypermagnesemia was inversely associated with all-cause mortality in patients with CKD and ESRD (HR 0.86; 95%CI 0.79–0.94; p = 0.001) . Moreover, a significant association between hypermagnesemia and decreased risk of cardiovascular mortality was observed (HR 0.71; 95% CI 053–0.97, p = 0.03) in the adjusted model. In addition,subgroup analysis found that hypomagnesemia was strongly associated with increased all-cause mortality in hemodialysis patients (HR 1.29; 95% CI 1.12–1.50; p = 0.0005).

Conclusion

Our results indicate that hypomagnesemia is significantly associated with cardiovascular and all-cause mortality
in patients with CKD and ESRD.

The association between hypomagnesemia and all-cause mortality for dichotomous variables (hypomagnesemia vs. normal magnesium or
hypermagnesemia group)
Fig.

The association between hypermagnesemia and all-cause mortality for continuous variables (hypermagnesemia vs. normal magnesium or
hypomagnesemia group)